345P The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study

G Liposits,L Poulsen Oestergaard,S.B Winther,J.S Johansen,P Pfeiffer,J Ryg,P.J Osterlund,C-H Shah,H Skuladottir,H Sorbye,C Qvortrup,E Hofsli,A Berglund,B Glimelius,S Möller

doi:10.1016/j.annonc.2022.07.483

345P The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study

G Liposits, L Poulsen Oestergaard + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.483

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#C-reactive Protein #Colorectal Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Proper patient selection for palliative chemotherapy is essential in patients with metastatic colorectal cancer (mCRC). C-reactive protein (CRP) and the derived neutrophil-to-lymphocyte ratio (dNLR) are available in clinical practice and may support prognostic understanding and decision-making. We studied the prognostic value of systemic inflammation through CRP, dNLR, Interleukin (IL)-6, and YKL-40 on progression-free survival (PFS) and overall survival (OS) in the NORDIC9 cohort including vulnerable older adults with mCRC.

Full Text